Sygnature Discovery appoints Dr Gerry Thomas as Director of Business Development
Sygnature Discovery Limited, the UK’s largest independent integrated drug discovery provider, today announced the appointment of Dr Gerry Thomas to the pivitol role of Director of Business Development.
Board Director, Dr Paul Clewlow, stated, “I am delighted to welcome Gerry Thomas to Sygnature Discovery. Gerry is a very experienced industry professional having spent over 20 years in drug discovery and development at Boots Pharmaceuticals, BASF/Knoll, OSI Pharmaceuticals, Prosidion and Shire Pharmaceuticals. Sygnature Discovery has ambitious plans to expand its customer base and Gerry will be instrumental in promoting Sygnature’s integrated drug discovery capabilities and expertise across Europe and North America. Gerry is a PhD medicinal chemist with considerable experience and an in-depth knowledge of the drug discovery and development process.”
Dr Gerry Thomas, Director of Business Development, added, “I am pleased to join Sygnature Discovery to work with Paul and his senior scientific colleagues and continue the impressive growth the company has been experiencing over the past 10 years. I know Sygnature well having been a client and was extremely impressed with their capabilities, expertise and determination to deliver on challenging drug discovery projects. So, when the opportunity arose, I was very happy to join the company. I am looking forward to the challenge of promoting Sygnature’s integrated drug discovery services using my know-how and experience in drug discovery and development.”